Introduction of a proposed National Prostate Cancer Council Act

So, according to a communication to its members from the American Urological Association (AUA), U.S. Senators Barbara Boxer (D, CA) and Jeff Sessions (R, AL) have just introduced S. 2813, the National Prostate Cancer Council Act. … READ MORE …

Prospective data on the use of MRI-guided vs. TRUS-guided biopsy

Two newly published papers in the November issue of the Journal of Urology address prospective studies of the use of differing forms of MRI-guided biopsy in the diagnosis of prostate cancer. … READ MORE …

Medicare may soon cover Prolaris, Decipher tests for prostate cancer

Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …

Neurocrine (small cell) cancer of the prostate: an update

A new review article in the open access journal Oncology offers some key information about neuroendocrine (small-cell) carcinomas of the prostate (and why they offer essential lessons about the diagnosis and management of prostate cancer). … READ MORE …

Expert opinions on prevention, screening, and active surveillance

There are three new and useful resources now available related to the prevention of prostate cancer, screening for prostate cancer, and the role of active surveillance in the expectant management of prostate cancer. … READ MORE …

Testosterone supplements, rats, and risk for prostate cancer in healthy, aging men

The “New” Prostate Cancer InfoLink has long argued that the use of testosterone supplements by otherwise healthy men as they age (as a way to try to maintain the vigor and libido of their youth) comes with risks, and that one of those risks is the risk for a diagnosis of prostate cancer. … READ MORE …

Genomic/genetic tests for risk for clinically significant prostate cancer

The precise ability of the various genetic/genomic tests now available to accurately analyze the risk for clinically significant prostate cancer based on biopsy tissue samples is an important factor that all of the different developers and manufacturers of these tests continue to study in greater detail. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,155 other followers